arrow_back Back Filing freshness 10-Q Q2 FY2026 SEC EDGAR

TREACE MEDICAL CONCEPTS, INC.

TMCI
$4.53 ▼ -0.05 (-1.20%) at close
Healthcare ·Surgical & Medical Instruments & Apparatus ·USSurgical & Medical Instruments & Apparatus
28 Visible periods
30 Metrics
Peer-ranked Benchmarks
Price Chart
21
Health
Poor
Bearish
auto_awesome

Analytical Summary

TREACE MEDICAL CONCEPTS, INC. faces fundamental challenges with weakness in Return on Common Equity (%) and Profit Margin (%). The fundamentals warrant careful consideration of downside risks.

Market Cap $294.7M
Dividend Yield
Revenue Growth -4.2%
Op. Margin -33.0%
ROIC -9.5%
FCF / Share $-0.11
Trailing P/E
Price / Book 4.4x
FCF Yield
Debt / Equity 0.87
info Valuation on last close. End-of-day price, Sep 23, 2026.

28-Year Financial Trajectory

Quarterly
Metric Value Trend Year over Year Percentile
Revenue Total top-line sales
$45.38M
↓ -4.2%
Net Income Profit after all expenses
$-17.96M
↓ -12.8%
Operating Margin Operating profit as % of sales
-33.0%
↑ +9.4% 9th
FCF / Share Free cash flow per share
$-0.11
↓ -264.0%
Long-Term Debt Long-term obligations
$56.04M
— +0.4%
trending_up

Bullish Indicators

  • No bullish signals detected.
warning

Bearish Risks

  • Operating Margin (%)Operating Margin (%) is in the bottom quartile
  • Profit Margin (%)Profit Margin (%) is in the bottom quartile
  • Return on Common Equity (%)Return on Common Equity (%) is in the bottom quartile

Health Breakdown

Profitability
9
Returns
13
Financial Health
36
Cash Quality
40

bar_chart Data from SEC EDGAR XBRL filings

Synced yesterday 8 years · 28 quarters